Journal: Canadian Respiratory Journal

Article Title: WuYeLuGen Granule Attenuates Bleomycin‐Induced Pulmonary Fibrosis in Rats by Inhibiting the TGF‐β1/Smad Signaling Pathway and Epithelial–Mesenchymal Transition

doi: 10.1155/carj/8103859

Figure Lengend Snippet: WYLG ameliorates TGF‐β1‐induced fibrotic changes in RPFs through the TGF‐β1/Smad signaling pathway. (a) Detection of α‐SMA content in cells by immunofluorescence (scale bar = 5 μm). (b) (A) The level of TGF‐β1/Smad signaling pathway protein in RPFs by WB to reflect the treatment of pulmonary fibrosis by WYLG. (b) (B) Densitometric quantification of TGF‐β1, Smad7, p‐Smad2 versus GAPDH for experiments in (b) (A). Meanwhile, the protein levels of p‐Smad2 should be normalized to those of Smad2 for quantitative analysis ( ^ p < 0.05, ∗∗/^^ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗/#### p < 0.0001; ∗ vs. CON group, # vs. MOD group, ^ vs. WYLG group).

Article Snippet: Rat pulmonary fibroblast cells (RPFs) were purchased from Procell Biotechnology Co., Ltd. (Wuhan, China).

Techniques: Immunofluorescence

Journal: PLOS One

Article Title: Pulmonary fibroblasts activated by the addition of TNF-α and IL-4 enhance lymphangiogenic capacity and ameliorate lung fibrosis in an allogeneic rat model

doi: 10.1371/journal.pone.0342528

Figure Lengend Snippet: (A) IVIS imaging performed one day after cell administration showing pulmonary localization of transplanted fibroblasts. (B) Representative Masson trichrome-stained lung sections from each group (Day 0, saline (Ctrl), rPF, and rPF + CKs). For each group, whole lung images (top row) and corresponding magnified views (bottom row) are shown to highlight differences in fibrosis and tissue architecture. (C) Quantification of fibrotic area. Data are presented as mean ± SEM. Statistical analysis was performed using the Kruskal–Wallis test, followed by Dunn’s multiple comparisons test. *p < 0.05, **p < 0.01 vs. indicated groups.

Article Snippet: Human pulmonary fibroblasts were purchased from PromoCell (Heidelberg, Germany) and cultured with HFDM-1(+) medium (Cell Science & Technology, Osaka, Japan) supplemented with 5% (v/v) Newborn Calf Serum (NBCS) and 1% (v/v) Penicillin-Streptomycin (P/S).

Techniques: Imaging, Staining, Saline

Journal: PLOS One

Article Title: Pulmonary fibroblasts activated by the addition of TNF-α and IL-4 enhance lymphangiogenic capacity and ameliorate lung fibrosis in an allogeneic rat model

doi: 10.1371/journal.pone.0342528

Figure Lengend Snippet: (A) Effect of allogeneic rPF or rPF + CKs cell treatment on plasma levels of surfactant protein D (SP-D) levels. (B) Effect of allogeneic rPF or rPF + CKs cell treatment on plasma fibrinogen levels.Pulmonary fibrosis was induced in mice (Day 0), followed by treatment with saline (Ctrl), allogeneic pulmonary fibroblasts (rPF), or cytokine-enriched fibroblasts (rPF + CKs).Plasma samples were collected on day 14 and analyzed for fibrinogen concentration using ELISA.Sample sizes (animal numbers) were as follows: SP-D: Day 0 = 8, Ctrl = 8, rPF = 8, rPF + CKs = 8 Fibrinogen: Day 0 = 7, Ctrl = 7, rPF = 7, rPF + CKs = 7.

Article Snippet: Human pulmonary fibroblasts were purchased from PromoCell (Heidelberg, Germany) and cultured with HFDM-1(+) medium (Cell Science & Technology, Osaka, Japan) supplemented with 5% (v/v) Newborn Calf Serum (NBCS) and 1% (v/v) Penicillin-Streptomycin (P/S).

Techniques: Clinical Proteomics, Saline, Concentration Assay, Enzyme-linked Immunosorbent Assay